These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 9450153

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of pivagabine on psychophysical performance and behavioural response in experimental models of stress.
    Scapagnini U, Matera M.
    Arzneimittelforschung; 1997 Nov; 47(11A):1310-4. PubMed ID: 9450154
    [Abstract] [Full Text] [Related]

  • 3. Effect of pivagabine on stress-induced gastric ulcer formation in rats.
    Gianni AM, Bruno G, Sirtori C.
    Arzneimittelforschung; 1997 Nov; 47(11A):1315-7. PubMed ID: 9450155
    [Abstract] [Full Text] [Related]

  • 4. Use of pivagabine in the management of hospitalization distress in children.
    Gelsomini S.
    Arzneimittelforschung; 1997 Nov; 47(11A):1332-5. PubMed ID: 9450160
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders.
    Negri L.
    Arzneimittelforschung; 1997 Nov; 47(11A):1322-5. PubMed ID: 9450157
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders.
    Terranova R, Gilotta SM, Luca S.
    Arzneimittelforschung; 1997 Nov; 47(11A):1325-8. PubMed ID: 9450158
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of pivagabine in the treatment of climacteric syndrome.
    Gigliotti B, Multinu A, Lai VR.
    Arzneimittelforschung; 1997 Nov; 47(11A):1317-21. PubMed ID: 9450156
    [Abstract] [Full Text] [Related]

  • 11. Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain.
    Serra M, Concas A, Mostallino MC, Chessa MF, Stomati M, Petraglia F, Genazzani AR, Biggio G.
    Psychoneuroendocrinology; 1999 Apr; 24(3):269-84. PubMed ID: 10101733
    [Abstract] [Full Text] [Related]

  • 12. [Search for and study of biologically active substances with psychotropic activity among the N-nicotinoyl derivatives of glutamic and gamma-aminobutyric acids].
    Kuz'menko GI, Gotsuliak LE, Gaĭdenko AI, Kazanov AD, Niiaka MF.
    Farmakol Toksikol; 1988 Apr; 51(1):12-4. PubMed ID: 2896131
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Psychopharmacologic profile of a new product: GABA linoleamide (Gabalid)].
    Vamvakidès A, Papadopoulou-Daïfoli Z.
    Agressologie; 1982 Oct; 23(4):123-4. PubMed ID: 7180983
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats.
    Engelborghs S, Pickut BA, D'Hooge R, Wiechert P, Haegele K, De Deyn PP.
    Arzneimittelforschung; 1998 Jul; 48(7):713-6. PubMed ID: 9706369
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Place of neurometabolic stimulators (cerebroprotectors) in the current systematics of psychotropic drugs and their principal kinds of clinical activity].
    Niss AI.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984 Jul; 84(5):750-6. PubMed ID: 6464593
    [Abstract] [Full Text] [Related]

  • 19. Effects of psychoactive agents on the brain.
    Sloviter HA.
    Psychopharmacol Bull; 1975 Jul; 11(3):71. PubMed ID: 1153683
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.